Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Valneva SE    VLA   FR0004056851

VALNEVA SE

(VLA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Valneva SE : No turn-around in sight

share with twitter share with LinkedIn share with facebook
09/18/2020 | 03:59am EDT
long trade
Live
Entry price : 6.34€ | Target : 7.8€ | Stop-loss : 5.2€ | Potential : 23.03%
Shares in Valneva SE show a positive technical chart pattern over the medium term, which suggests that the rising trend should be followed.
Investors have an opportunity to buy the stock and target the € 7.8.
Valneva SE : Valneva SE : No turn-around in sight
Strengths
  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • Over the last seven days, analysts have been revising upwards their EPS estimates for the company.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 3.45 EUR

Weaknesses
  • The company has insufficient levels of profitability.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The company's enterprise value to sales, at 4.37 times its current sales, is high.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart
Subsector Biotechnology & Medical Research - NEC
1st jan.Capitalization (M$)Investor Rating
VALNEVA SE131.13%638
LONZA GROUP AG56.63%44 852
SEAGEN INC.68.34%33 467
CELLTRION, INC.33.15%29 849
IQVIA HOLDINGS INC.-0.34%29 650
MODERNA, INC.264.42%28 126
IMMUNOMEDICS, INC.315.22%20 324
INCYTE CORPORATION-0.78%19 031
HANGZHOU TIGERMED CONSULTIN..96.36%16 284
ALNYLAM PHARMACEUTICALS, IN..6.77%14 301
PHARMARON BEIJING CO., LTD.123.13%13 451
More Results


share with twitter share with LinkedIn share with facebook

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials
Sales 2020 127 M 147 M 147 M
Net income 2020 -30,4 M -35,4 M -35,4 M
Net cash 2020 56,6 M 65,9 M 65,9 M
P/E ratio 2020 -18,3x
Yield 2020 -
Capitalization 561 M 654 M 653 M
EV / Sales 2020 3,98x
EV / Sales 2021 1,89x
Nbr of Employees 500
Free-Float 69,1%
Upcoming event on VALNEVA SE
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 8,66 €
Last Close Price 6,09 €
Spread / Highest target 49,4%
Spread / Average Target 42,2%
Spread / Lowest Target 18,2%
EPS Revisions
Managers
NameTitle
Thomas Lingelbach Co-President & Chief Executive Officer
Franck Charles Marie Grimaud Co-President & Chief Business Officer
Frédéric Grimaud Chairman-Supervisory Board
David Muir Lawrence Chief Financial Officer
Michael Möhlen Vice President-Technical Development